Objective
Antimicrobial-resistant and persistent bacterial infections represent major global healthcare challenges, imposing substantial costs and highlighting the urgent need for new and more effective treatment options. The World Health Organization and other international bodies have identified critical gaps in the current antibacterial drug discovery pipeline, which relies heavily on similar mechanisms of action and fails to address the needs of low- and middle-income countries. The rapid emergence of bacterial resistance, coupled with a lack of globally applicable therapeutics, continues to exacerbate the antimicrobial resistance (AMR) crisis.
The European Novel Drug Research to Address Microbial Infections and Drug Resistance (END2AMR) consortium aims to tackle these challenges by developing innovative therapeutic modalities and delivery technologies that can overcome current treatment limitations. END2AMR brings together a multidisciplinary public–private partnership comprising pharmaceutical, biotechnology, and academic expertise to advance a diverse portfolio of novel antibacterial modalities and delivery technologies. These will be applied independently or in combination to improve patient outcomes, using specific bacterial pathogen case studies as a basis for broader translational impact. The case studies targeting specific bacterial pathogens will serve as exemplars to extend these approaches to other infectious diseases.
Main Objectives:
• Advance and validate innovative strategies to treat chronic and drug-resistant bacterial infections, with particular emphasis on Gram-negative bacteria and mycobacteria.
• Develop a versatile toolkit to enable the creation, optimization, and translation of next-generation antibacterial treatments.
Key Deliverables:
• Demonstrate proof of concept for at least three new antibacterial modalities and/or delivery technologies addressing infections currently lacking effective therapies.
• Progress at least one long-acting therapeutic to preclinical candidate status.
Long-Term Impact:
END2AMR will establish robust pathways for antibacterial drug discovery and development, including Target Product Profiles for novel modalities and delivery technologies. The project will also create a framework to support the translation and exploitation of innovative approaches generated through its activities. Ultimately, END2AMR will strengthen the European health innovation ecosystem, enhancing preparedness, resilience, and global leadership in addressing chronic bacterial infections and antimicrobial resistance through both traditional and pioneering approaches.
Acknowledgement
END2AMR is supported by the Innovative Health Initiative Joint Undertaking (IHI JU). The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bio, MedTech Europe, and Vaccines Europe.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology bacteriology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme -
HORIZON.2.1.7 - Innovative Health Initiative
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-JU-IHI-2025-09-single-stage
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
3521 AL Utrecht
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.